Tuesday, July 21, 2009 8:29:44 AM
A more obvious and egregious breach of fiduciary duty was Mr. Lanzafame's extraordinary move to sell the Myotech CSS technology at a knock down price to his own shell company set up by him with his pal Frank Terrizzi.
I can only think Mr. Lanzafame didn't realise that a DNS search of MyoCardioCare (thank you b9molecule) would reveal that he was the founder.
It was also interesting that the contract appended to the SEC filing had Lanzafame's signature as BIPH's CEO, but Terrizzi's signature as MyoCardioCare's President.
They must think Biophan shareholders are an extraordinarily naive and gullible group (!).
That said this is certainly an actionable breach of both fiduciary duty but also of securities legislation. Not the first by this bunch, and probably not the last, but perhaps the one which will break the camel's back?
For the sake of justice and good order in the financial markets, let's hope so.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM